Elizabeth Brickley
Concepts (354)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Zika Virus Infection | 55 | 2026 | 168 | 11.140 |
Why?
| | Zika Virus | 43 | 2026 | 132 | 7.910 |
Why?
| | Microcephaly | 33 | 2026 | 103 | 4.730 |
Why?
| | Pregnancy Complications, Infectious | 30 | 2026 | 428 | 3.670 |
Why?
| | Poliomyelitis | 9 | 2025 | 35 | 2.850 |
Why?
| | Brazil | 57 | 2026 | 180 | 2.760 |
Why?
| | Poliovirus Vaccine, Oral | 6 | 2025 | 25 | 2.190 |
Why?
| | Poliovirus Vaccine, Inactivated | 6 | 2024 | 27 | 2.050 |
Why?
| | Poliovirus | 6 | 2025 | 73 | 1.980 |
Why?
| | Antibodies, Viral | 11 | 2026 | 672 | 1.630 |
Why?
| | Dengue | 4 | 2025 | 89 | 1.500 |
Why?
| | Arboviruses | 2 | 2022 | 14 | 1.470 |
Why?
| | Leprosy | 8 | 2025 | 25 | 1.340 |
Why?
| | Immunity, Mucosal | 7 | 2025 | 98 | 1.280 |
Why?
| | Malaria | 5 | 2019 | 73 | 1.220 |
Why?
| | Epidemics | 4 | 2021 | 98 | 1.080 |
Why?
| | Prenatal Exposure Delayed Effects | 11 | 2025 | 675 | 1.070 |
Why?
| | Antibodies, Neutralizing | 10 | 2026 | 341 | 1.060 |
Why?
| | Anemia | 4 | 2019 | 188 | 1.040 |
Why?
| | Immunoglobulin A | 8 | 2025 | 214 | 1.000 |
Why?
| | Infant | 46 | 2026 | 10039 | 0.960 |
Why?
| | Pregnancy | 45 | 2026 | 7191 | 0.910 |
Why?
| | Disease Outbreaks | 9 | 2024 | 422 | 0.880 |
Why?
| | Vaccines, Attenuated | 3 | 2022 | 129 | 0.880 |
Why?
| | Fetal Blood | 3 | 2017 | 342 | 0.880 |
Why?
| | Chikungunya Fever | 2 | 2024 | 84 | 0.870 |
Why?
| | Cohort Studies | 29 | 2026 | 5965 | 0.800 |
Why?
| | Socioeconomic Factors | 14 | 2025 | 1327 | 0.780 |
Why?
| | Virus Diseases | 3 | 2021 | 216 | 0.730 |
Why?
| | Infant, Newborn | 34 | 2026 | 6434 | 0.730 |
Why?
| | Chikungunya virus | 2 | 2024 | 86 | 0.720 |
Why?
| | Arbovirus Infections | 1 | 2022 | 20 | 0.710 |
Why?
| | Feces | 4 | 2022 | 513 | 0.700 |
Why?
| | Child, Preschool | 38 | 2025 | 11799 | 0.700 |
Why?
| | Vaccines, Inactivated | 2 | 2019 | 70 | 0.700 |
Why?
| | Mosquito Vectors | 2 | 2022 | 28 | 0.670 |
Why?
| | Humans | 112 | 2026 | 144957 | 0.670 |
Why?
| | Malaria Vaccines | 2 | 2017 | 11 | 0.630 |
Why?
| | Communicable Diseases, Emerging | 1 | 2020 | 38 | 0.630 |
Why?
| | Intestinal Mucosa | 3 | 2025 | 676 | 0.600 |
Why?
| | Female | 76 | 2026 | 78376 | 0.580 |
Why?
| | Workplace | 4 | 2024 | 274 | 0.570 |
Why?
| | Coinfection | 1 | 2020 | 141 | 0.560 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 384 | 0.560 |
Why?
| | Coronavirus Infections | 2 | 2020 | 378 | 0.560 |
Why?
| | Influenza Vaccines | 2 | 2019 | 529 | 0.530 |
Why?
| | Anopheles | 1 | 2016 | 17 | 0.500 |
Why?
| | Malaria, Falciparum | 1 | 2016 | 33 | 0.490 |
Why?
| | Hepcidins | 1 | 2016 | 22 | 0.490 |
Why?
| | Vaccination | 6 | 2024 | 1423 | 0.480 |
Why?
| | Young Adult | 25 | 2026 | 14126 | 0.440 |
Why?
| | Fetal Diseases | 3 | 2021 | 191 | 0.410 |
Why?
| | Adult | 40 | 2026 | 40506 | 0.410 |
Why?
| | Iron | 1 | 2016 | 359 | 0.400 |
Why?
| | Immunoglobulin G | 7 | 2026 | 893 | 0.390 |
Why?
| | Influenza, Human | 1 | 2019 | 617 | 0.390 |
Why?
| | Male | 46 | 2025 | 72406 | 0.390 |
Why?
| | Pandemics | 2 | 2020 | 1695 | 0.370 |
Why?
| | Nervous System Malformations | 2 | 2023 | 47 | 0.360 |
Why?
| | Child | 27 | 2025 | 22657 | 0.350 |
Why?
| | Cross-Sectional Studies | 11 | 2025 | 5872 | 0.350 |
Why?
| | Leprosy, Multibacillary | 2 | 2021 | 2 | 0.340 |
Why?
| | Fetus | 2 | 2021 | 803 | 0.330 |
Why?
| | Tuberculosis | 2 | 2025 | 291 | 0.330 |
Why?
| | Exanthema | 2 | 2023 | 84 | 0.330 |
Why?
| | Cryptorchidism | 2 | 2020 | 17 | 0.320 |
Why?
| | Incidence | 11 | 2025 | 2883 | 0.310 |
Why?
| | Adolescent | 19 | 2025 | 22453 | 0.300 |
Why?
| | Biomarkers | 5 | 2020 | 4275 | 0.290 |
Why?
| | Immunoglobulin M | 5 | 2026 | 284 | 0.290 |
Why?
| | Poliovirus Vaccines | 2 | 2019 | 6 | 0.270 |
Why?
| | Virus Shedding | 4 | 2021 | 48 | 0.260 |
Why?
| | Middle Aged | 21 | 2025 | 35928 | 0.260 |
Why?
| | Infant Mortality | 3 | 2024 | 123 | 0.260 |
Why?
| | Prospective Studies | 14 | 2025 | 7997 | 0.250 |
Why?
| | Maternal Exposure | 2 | 2021 | 213 | 0.250 |
Why?
| | Parturition | 3 | 2023 | 69 | 0.250 |
Why?
| | Neurodevelopmental Disorders | 2 | 2020 | 227 | 0.250 |
Why?
| | Urban Population | 2 | 2020 | 491 | 0.250 |
Why?
| | Cytokines | 1 | 2014 | 2065 | 0.240 |
Why?
| | Risk Factors | 14 | 2025 | 10792 | 0.240 |
Why?
| | Pregnancy Outcome | 4 | 2025 | 476 | 0.240 |
Why?
| | Social Segregation | 1 | 2025 | 3 | 0.230 |
Why?
| | Public Housing | 1 | 2025 | 10 | 0.230 |
Why?
| | Adenoids | 2 | 2024 | 12 | 0.220 |
Why?
| | Risk | 3 | 2020 | 911 | 0.220 |
Why?
| | Respiratory Syncytial Viruses | 1 | 2025 | 58 | 0.220 |
Why?
| | Case-Control Studies | 4 | 2021 | 3608 | 0.210 |
Why?
| | Pharynx | 1 | 2024 | 59 | 0.210 |
Why?
| | Language Development Disorders | 2 | 2022 | 40 | 0.210 |
Why?
| | Hearing Loss, Sensorineural | 1 | 2025 | 73 | 0.210 |
Why?
| | Income | 1 | 2025 | 202 | 0.210 |
Why?
| | Cold Temperature | 1 | 2025 | 209 | 0.210 |
Why?
| | Prevalence | 6 | 2023 | 2836 | 0.200 |
Why?
| | Transients and Migrants | 1 | 2023 | 27 | 0.200 |
Why?
| | Americas | 2 | 2020 | 26 | 0.200 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2025 | 157 | 0.200 |
Why?
| | Bayes Theorem | 2 | 2022 | 433 | 0.190 |
Why?
| | Meta-Analysis as Topic | 2 | 2021 | 174 | 0.190 |
Why?
| | Hospitalization | 2 | 2025 | 2434 | 0.190 |
Why?
| | Epilepsies, Partial | 2 | 2023 | 63 | 0.190 |
Why?
| | Mortality | 1 | 2025 | 376 | 0.190 |
Why?
| | Racism | 1 | 2025 | 151 | 0.190 |
Why?
| | Belgium | 1 | 2022 | 11 | 0.190 |
Why?
| | Smokers | 1 | 2023 | 137 | 0.190 |
Why?
| | Hot Temperature | 1 | 2025 | 407 | 0.190 |
Why?
| | Viruses, Unclassified | 1 | 2022 | 4 | 0.190 |
Why?
| | Respiratory Tract Infections | 2 | 2024 | 398 | 0.180 |
Why?
| | Electroencephalography | 2 | 2023 | 551 | 0.180 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2025 | 636 | 0.180 |
Why?
| | Urinary Tract | 1 | 2022 | 49 | 0.180 |
Why?
| | United Kingdom | 2 | 2020 | 338 | 0.180 |
Why?
| | Family Characteristics | 2 | 2020 | 197 | 0.180 |
Why?
| | Hospital Records | 1 | 2021 | 10 | 0.180 |
Why?
| | Nervous System | 1 | 2022 | 70 | 0.170 |
Why?
| | Child Mortality | 1 | 2021 | 16 | 0.170 |
Why?
| | Serogroup | 2 | 2018 | 44 | 0.170 |
Why?
| | Hearing Loss | 1 | 2025 | 247 | 0.170 |
Why?
| | Antibody Formation | 1 | 2022 | 294 | 0.170 |
Why?
| | Orchiopexy | 1 | 2020 | 7 | 0.170 |
Why?
| | Control Groups | 1 | 2020 | 12 | 0.170 |
Why?
| | Epilepsy | 2 | 2023 | 387 | 0.170 |
Why?
| | Environmental Exposure | 1 | 2025 | 590 | 0.170 |
Why?
| | Public Assistance | 1 | 2020 | 19 | 0.160 |
Why?
| | Epidemiologic Research Design | 1 | 2020 | 29 | 0.160 |
Why?
| | Language Development | 1 | 2021 | 60 | 0.160 |
Why?
| | Air Pollution | 1 | 2024 | 327 | 0.160 |
Why?
| | Endocrine System Diseases | 1 | 2020 | 35 | 0.160 |
Why?
| | Betacoronavirus | 2 | 2020 | 286 | 0.160 |
Why?
| | Cerebral Palsy | 1 | 2023 | 132 | 0.160 |
Why?
| | Motor Skills | 1 | 2021 | 104 | 0.160 |
Why?
| | Pregnancy, Twin | 1 | 2020 | 19 | 0.160 |
Why?
| | Leprostatic Agents | 1 | 2020 | 6 | 0.160 |
Why?
| | Central Nervous System Diseases | 1 | 2021 | 74 | 0.160 |
Why?
| | Viral Vaccines | 1 | 2021 | 107 | 0.160 |
Why?
| | Cross-Cultural Comparison | 1 | 2020 | 84 | 0.160 |
Why?
| | Breast Feeding | 1 | 2024 | 448 | 0.160 |
Why?
| | Respiratory Sounds | 1 | 2020 | 105 | 0.160 |
Why?
| | England | 3 | 2024 | 111 | 0.160 |
Why?
| | Tanzania | 2 | 2019 | 73 | 0.160 |
Why?
| | Malformations of Cortical Development | 1 | 2020 | 19 | 0.160 |
Why?
| | Plasmodium | 1 | 2019 | 13 | 0.160 |
Why?
| | Developing Countries | 2 | 2019 | 318 | 0.150 |
Why?
| | Coronavirus | 1 | 2020 | 47 | 0.150 |
Why?
| | Receptors, Complement 3b | 1 | 2019 | 80 | 0.150 |
Why?
| | Hemagglutination Inhibition Tests | 1 | 2019 | 38 | 0.150 |
Why?
| | Air Pollutants | 1 | 2024 | 438 | 0.150 |
Why?
| | Cesarean Section | 1 | 2021 | 224 | 0.150 |
Why?
| | Bangladesh | 1 | 2019 | 62 | 0.150 |
Why?
| | Protozoan Proteins | 2 | 2017 | 93 | 0.150 |
Why?
| | Prenatal Diagnosis | 1 | 2021 | 195 | 0.150 |
Why?
| | Administration, Intranasal | 1 | 2019 | 93 | 0.150 |
Why?
| | Urbanization | 1 | 2019 | 28 | 0.150 |
Why?
| | Infant, Newborn, Diseases | 1 | 2021 | 113 | 0.150 |
Why?
| | Influenza A Virus, H3N2 Subtype | 1 | 2019 | 50 | 0.150 |
Why?
| | N-Acetylneuraminic Acid | 1 | 2019 | 16 | 0.150 |
Why?
| | Birth Certificates | 1 | 2019 | 12 | 0.150 |
Why?
| | Travel | 1 | 2020 | 136 | 0.150 |
Why?
| | Intestines | 2 | 2021 | 358 | 0.150 |
Why?
| | Registries | 6 | 2025 | 2385 | 0.150 |
Why?
| | Death Certificates | 1 | 2019 | 32 | 0.150 |
Why?
| | Chile | 1 | 2018 | 26 | 0.140 |
Why?
| | Deglutition Disorders | 1 | 2020 | 147 | 0.140 |
Why?
| | Esophageal Neoplasms | 1 | 2022 | 349 | 0.140 |
Why?
| | Comorbidity | 2 | 2020 | 1660 | 0.140 |
Why?
| | Longitudinal Studies | 5 | 2026 | 2947 | 0.140 |
Why?
| | Medical Record Linkage | 1 | 2019 | 68 | 0.140 |
Why?
| | Follow-Up Studies | 7 | 2023 | 5417 | 0.140 |
Why?
| | Developmental Disabilities | 1 | 2021 | 281 | 0.140 |
Why?
| | Asthma | 2 | 2020 | 1768 | 0.140 |
Why?
| | Immunoglobulin D | 1 | 2018 | 29 | 0.140 |
Why?
| | Communicable Diseases | 1 | 2020 | 163 | 0.140 |
Why?
| | Sporozoites | 1 | 2017 | 1 | 0.140 |
Why?
| | Spasms, Infantile | 1 | 2020 | 136 | 0.130 |
Why?
| | Rural Population | 2 | 2021 | 650 | 0.130 |
Why?
| | Research | 1 | 2021 | 431 | 0.130 |
Why?
| | Plasmodium falciparum | 1 | 2017 | 39 | 0.130 |
Why?
| | Nervous System Diseases | 1 | 2020 | 284 | 0.130 |
Why?
| | Rectus Abdominis | 1 | 2017 | 16 | 0.130 |
Why?
| | Patient Participation | 1 | 2021 | 433 | 0.130 |
Why?
| | Milk, Human | 1 | 2019 | 172 | 0.130 |
Why?
| | Gestational Age | 4 | 2022 | 975 | 0.130 |
Why?
| | Databases, Factual | 2 | 2021 | 1486 | 0.120 |
Why?
| | Endothelium | 1 | 2017 | 119 | 0.120 |
Why?
| | Esophageal Motility Disorders | 1 | 2016 | 29 | 0.120 |
Why?
| | Sepsis | 1 | 2023 | 641 | 0.120 |
Why?
| | Free Tissue Flaps | 1 | 2017 | 45 | 0.120 |
Why?
| | Arsenic | 1 | 2017 | 66 | 0.120 |
Why?
| | Smoking | 1 | 2023 | 1472 | 0.120 |
Why?
| | Esophagitis | 1 | 2016 | 66 | 0.120 |
Why?
| | Body Composition | 1 | 2019 | 706 | 0.120 |
Why?
| | Mammaplasty | 1 | 2017 | 104 | 0.110 |
Why?
| | Adenocarcinoma | 1 | 2022 | 931 | 0.110 |
Why?
| | Social Determinants of Health | 1 | 2019 | 301 | 0.110 |
Why?
| | Deficiency Diseases | 1 | 2014 | 10 | 0.110 |
Why?
| | Wasting Syndrome | 1 | 2014 | 12 | 0.110 |
Why?
| | Child Nutrition Disorders | 1 | 2014 | 20 | 0.110 |
Why?
| | Lymphocytes | 1 | 2016 | 382 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type II | 1 | 2014 | 41 | 0.110 |
Why?
| | Esophagus | 1 | 2016 | 261 | 0.110 |
Why?
| | Receptors, Tumor Necrosis Factor, Type I | 1 | 2014 | 81 | 0.110 |
Why?
| | Dendritic Cells | 1 | 2017 | 499 | 0.100 |
Why?
| | Tissue Donors | 1 | 2017 | 424 | 0.100 |
Why?
| | Pregnancy Complications | 1 | 2019 | 592 | 0.100 |
Why?
| | Erythrocytes | 1 | 2019 | 757 | 0.100 |
Why?
| | Ecuador | 2 | 2024 | 13 | 0.090 |
Why?
| | Interleukins | 1 | 2014 | 248 | 0.090 |
Why?
| | Cognition | 1 | 2021 | 1269 | 0.090 |
Why?
| | Animals | 5 | 2022 | 38109 | 0.090 |
Why?
| | Skin | 1 | 2016 | 758 | 0.090 |
Why?
| | Cause of Death | 2 | 2025 | 472 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2016 | 1054 | 0.090 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2017 | 917 | 0.080 |
Why?
| | Diet | 1 | 2019 | 1275 | 0.080 |
Why?
| | Interferon-gamma | 1 | 2014 | 784 | 0.080 |
Why?
| | Feeding Behavior | 1 | 2016 | 685 | 0.080 |
Why?
| | Occupational Exposure | 2 | 2024 | 354 | 0.080 |
Why?
| | Neuroimaging | 2 | 2023 | 292 | 0.080 |
Why?
| | Growth Disorders | 2 | 2024 | 86 | 0.080 |
Why?
| | Tumor Necrosis Factor-alpha | 1 | 2014 | 1217 | 0.070 |
Why?
| | Retrospective Studies | 4 | 2022 | 17101 | 0.070 |
Why?
| | T-Lymphocytes | 1 | 2017 | 1982 | 0.070 |
Why?
| | Infectious Disease Transmission, Vertical | 2 | 2021 | 193 | 0.070 |
Why?
| | Latin America | 2 | 2020 | 94 | 0.070 |
Why?
| | Cerebral Cortex | 2 | 2023 | 465 | 0.070 |
Why?
| | RNA, Viral | 2 | 2023 | 688 | 0.070 |
Why?
| | Polymerase Chain Reaction | 2 | 2020 | 1054 | 0.060 |
Why?
| | Treatment Outcome | 4 | 2025 | 11695 | 0.060 |
Why?
| | Spatial Analysis | 1 | 2025 | 23 | 0.060 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 2025 | 3 | 0.060 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2025 | 77 | 0.060 |
Why?
| | Surveys and Questionnaires | 3 | 2024 | 6053 | 0.050 |
Why?
| | Serum | 1 | 2025 | 59 | 0.050 |
Why?
| | Postoperative Complications | 1 | 2017 | 2920 | 0.050 |
Why?
| | Aged | 4 | 2025 | 25947 | 0.050 |
Why?
| | Ventilation | 1 | 2024 | 46 | 0.050 |
Why?
| | Nasal Mucosa | 1 | 2024 | 112 | 0.050 |
Why?
| | Contact Tracing | 1 | 2023 | 26 | 0.050 |
Why?
| | Manufacturing and Industrial Facilities | 1 | 2023 | 2 | 0.050 |
Why?
| | Alpha Rhythm | 1 | 2023 | 11 | 0.050 |
Why?
| | HIV Infections | 1 | 2019 | 3154 | 0.050 |
Why?
| | Health Status Indicators | 1 | 2024 | 166 | 0.050 |
Why?
| | Theta Rhythm | 1 | 2023 | 18 | 0.050 |
Why?
| | Cross-Over Studies | 1 | 2025 | 601 | 0.050 |
Why?
| | Plastics | 1 | 2023 | 47 | 0.050 |
Why?
| | Sleep Stages | 1 | 2023 | 75 | 0.050 |
Why?
| | Information Storage and Retrieval | 1 | 2023 | 121 | 0.050 |
Why?
| | Eye Movements | 1 | 2023 | 92 | 0.050 |
Why?
| | Kinetics | 1 | 2026 | 1629 | 0.050 |
Why?
| | Temperature | 1 | 2025 | 679 | 0.050 |
Why?
| | Spatio-Temporal Analysis | 1 | 2022 | 39 | 0.050 |
Why?
| | DNA Viruses | 1 | 2022 | 23 | 0.050 |
Why?
| | Radionuclide Imaging | 1 | 2022 | 113 | 0.050 |
Why?
| | Urodynamics | 1 | 2022 | 47 | 0.040 |
Why?
| | Wakefulness | 1 | 2023 | 169 | 0.040 |
Why?
| | Esophagectomy | 1 | 2022 | 135 | 0.040 |
Why?
| | Particulate Matter | 1 | 2024 | 347 | 0.040 |
Why?
| | Spike Glycoprotein, Coronavirus | 1 | 2022 | 130 | 0.040 |
Why?
| | Evoked Potentials, Auditory | 1 | 2022 | 180 | 0.040 |
Why?
| | Parity | 1 | 2021 | 109 | 0.040 |
Why?
| | Age of Onset | 1 | 2023 | 551 | 0.040 |
Why?
| | Carbon Dioxide | 1 | 2023 | 242 | 0.040 |
Why?
| | Population Groups | 1 | 2021 | 58 | 0.040 |
Why?
| | Lithuania | 1 | 2021 | 1 | 0.040 |
Why?
| | Diagnostic Techniques, Surgical | 1 | 2020 | 1 | 0.040 |
Why?
| | Caribbean Region | 1 | 2020 | 30 | 0.040 |
Why?
| | Testicular Diseases | 1 | 2020 | 6 | 0.040 |
Why?
| | Pregnancy, High-Risk | 1 | 2020 | 14 | 0.040 |
Why?
| | Immunogenicity, Vaccine | 1 | 2021 | 36 | 0.040 |
Why?
| | Asymptomatic Infections | 1 | 2020 | 37 | 0.040 |
Why?
| | Hypertrophy | 1 | 2021 | 127 | 0.040 |
Why?
| | Infection Control | 1 | 2022 | 172 | 0.040 |
Why?
| | World Health Organization | 1 | 2020 | 105 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 83 | 0.040 |
Why?
| | Delivery, Obstetric | 1 | 2021 | 160 | 0.040 |
Why?
| | Fetal Death | 1 | 2020 | 58 | 0.040 |
Why?
| | Maternal Age | 1 | 2020 | 126 | 0.040 |
Why?
| | Causality | 1 | 2020 | 126 | 0.040 |
Why?
| | Treatment Adherence and Compliance | 1 | 2020 | 27 | 0.040 |
Why?
| | Clinical Laboratory Techniques | 1 | 2020 | 96 | 0.040 |
Why?
| | Macaca fascicularis | 1 | 2019 | 71 | 0.040 |
Why?
| | Neutralization Tests | 1 | 2019 | 76 | 0.040 |
Why?
| | Symptom Assessment | 1 | 2020 | 137 | 0.040 |
Why?
| | Neoadjuvant Therapy | 1 | 2022 | 463 | 0.040 |
Why?
| | Cross Reactions | 1 | 2019 | 130 | 0.040 |
Why?
| | Infant, Low Birth Weight | 1 | 2020 | 153 | 0.040 |
Why?
| | Clinical Protocols | 1 | 2021 | 282 | 0.040 |
Why?
| | Macaca mulatta | 1 | 2019 | 191 | 0.040 |
Why?
| | Child Development | 1 | 2024 | 484 | 0.040 |
Why?
| | Maternal Death | 1 | 2019 | 15 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 966 | 0.040 |
Why?
| | Live Birth | 1 | 2019 | 68 | 0.040 |
Why?
| | Maternal Mortality | 1 | 2019 | 53 | 0.040 |
Why?
| | Cities | 1 | 2019 | 143 | 0.040 |
Why?
| | Mosquito Control | 1 | 2019 | 29 | 0.040 |
Why?
| | Length of Stay | 1 | 2025 | 1337 | 0.040 |
Why?
| | Educational Status | 1 | 2021 | 467 | 0.040 |
Why?
| | Seizures | 1 | 2023 | 477 | 0.040 |
Why?
| | Birth Weight | 1 | 2022 | 522 | 0.040 |
Why?
| | Uterus | 1 | 2020 | 226 | 0.040 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2025 | 1721 | 0.030 |
Why?
| | Stillbirth | 1 | 2019 | 77 | 0.030 |
Why?
| | Species Specificity | 1 | 2019 | 574 | 0.030 |
Why?
| | CD4 Lymphocyte Count | 1 | 2019 | 277 | 0.030 |
Why?
| | Global Health | 1 | 2021 | 401 | 0.030 |
Why?
| | Capacity Building | 1 | 2019 | 62 | 0.030 |
Why?
| | Odds Ratio | 1 | 2021 | 1077 | 0.030 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 280 | 0.030 |
Why?
| | Mali | 1 | 2017 | 3 | 0.030 |
Why?
| | Congenital Abnormalities | 1 | 2019 | 104 | 0.030 |
Why?
| | Ultrasonography, Prenatal | 1 | 2020 | 294 | 0.030 |
Why?
| | CD8 Antigens | 1 | 2017 | 72 | 0.030 |
Why?
| | Antibodies, Protozoan | 1 | 2017 | 41 | 0.030 |
Why?
| | New Hampshire | 1 | 2017 | 12 | 0.030 |
Why?
| | Anticonvulsants | 1 | 2020 | 242 | 0.030 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2017 | 100 | 0.030 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2019 | 851 | 0.030 |
Why?
| | United States | 2 | 2025 | 15988 | 0.030 |
Why?
| | Inflammation | 2 | 2019 | 2880 | 0.030 |
Why?
| | Immunity | 1 | 2017 | 139 | 0.030 |
Why?
| | Prenatal Care | 1 | 2019 | 307 | 0.030 |
Why?
| | Lymphocyte Count | 1 | 2016 | 164 | 0.030 |
Why?
| | Biomedical Research | 1 | 2023 | 710 | 0.030 |
Why?
| | Mastectomy | 1 | 2017 | 162 | 0.030 |
Why?
| | Body Weight | 1 | 2019 | 978 | 0.030 |
Why?
| | Population Surveillance | 1 | 2019 | 485 | 0.030 |
Why?
| | Immunization Schedule | 1 | 2016 | 187 | 0.030 |
Why?
| | Africa South of the Sahara | 1 | 2014 | 53 | 0.030 |
Why?
| | Graft Survival | 1 | 2017 | 526 | 0.030 |
Why?
| | Mothers | 1 | 2020 | 775 | 0.030 |
Why?
| | Observational Studies as Topic | 1 | 2014 | 129 | 0.030 |
Why?
| | Peptide Fragments | 1 | 2017 | 699 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2016 | 1048 | 0.020 |
Why?
| | Placenta | 1 | 2020 | 780 | 0.020 |
Why?
| | Biopsy | 1 | 2016 | 1077 | 0.020 |
Why?
| | Qualitative Research | 1 | 2021 | 1671 | 0.020 |
Why?
| | Research Design | 1 | 2019 | 1137 | 0.020 |
Why?
| | Age Factors | 1 | 2020 | 3335 | 0.020 |
Why?
| | Algorithms | 1 | 2019 | 1839 | 0.020 |
Why?
| | Mass Screening | 1 | 2020 | 1348 | 0.020 |
Why?
| | Logistic Models | 1 | 2016 | 2119 | 0.020 |
Why?
| | Health Services Accessibility | 1 | 2019 | 1099 | 0.020 |
Why?
| | Body Mass Index | 1 | 2019 | 2438 | 0.020 |
Why?
| | Cell Proliferation | 1 | 2017 | 2499 | 0.020 |
Why?
| | Cells, Cultured | 1 | 2017 | 4155 | 0.020 |
Why?
| | Tomography, X-Ray Computed | 1 | 2020 | 2738 | 0.020 |
Why?
| | Liver | 1 | 2017 | 1888 | 0.020 |
Why?
| | Disease Progression | 1 | 2016 | 2852 | 0.020 |
Why?
| | Home Care Services | 1 | 1971 | 280 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 1 | 2020 | 3869 | 0.020 |
Why?
| | Disease Models, Animal | 1 | 2017 | 4569 | 0.020 |
Why?
| | Medicare | 1 | 1971 | 887 | 0.010 |
Why?
| | Mice | 1 | 2017 | 18365 | 0.010 |
Why?
| | Nebraska | 1 | 1971 | 21 | 0.010 |
Why?
|
|
Brickley's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|